BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 6.958

Change

+0.06 (+0.88)%

Market Cap

N/A

Volume

120.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+1.07 (+0.92%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.10 (-0.54%)

USD 557.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.03 (-0.19%)

USD 496.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.60 (+0.84%)

USD 266.08B
0QZO:LSE 0QZO

+0.65 (+0.71%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+2.09 (+1.27%)

USD 202.26B
PRJU:LSE Amundi Index Solutions - Amund..

-0.13 (-0.41%)

USD 200.01B
0R24:LSE Intel Corp.

+1.67 (+8.20%)

USD 196.14B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.01% 70% C- 66% D+
Dividend Return 0.27% 38% F 67% D+
Total Return 9.28% 69% C- 66% D+
Trailing 12 Months  
Capital Gain 17.03% 75% C 71% C-
Dividend Return 0.29% 38% F 66% D+
Total Return 17.32% 75% C 71% C-
Trailing 5 Years  
Capital Gain 45.58% 68% D+ 73% C
Dividend Return 0.97% 27% F 28% F
Total Return 46.55% 67% D+ 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.10% 51% F 57% F
Dividend Return 5.22% 51% F 56% F
Total Return 0.12% 31% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 18.74% 37% F 53% F
Risk Adjusted Return 27.86% 45% F 59% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.